Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
TUESDAY, July 20, 2021 -- For older adults with atrial fibrillation, apixaban is associated with lower rates of adverse events than warfarin across all frailty levels, according to a study published online July 20 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2021 Category: Pharmaceuticals Source Type: news

Coffee consumption cuts risk for heart arrythmia, AFib, study finds
A study published Monday disputes the common notion that drinking caffeine increases risk for heart ailments, including atrial fibrillation. In fact, the risk declines by 3% to 4% for each cup of coffee consumed. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 19, 2021 Category: Consumer Health News Source Type: news

Study IDs risk factors for irregular heartbeats in hypertrophic cardiomyopathy patients
(University of Virginia Health System) The new research will help doctors identify, treat and prevent dangerous atrial fibrillation in patients with hypertrophic cardiomyopathy, a common heart condition. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Athletes Face Twice the Odds for A-Fib
A new report finds athletes have a much higher risk of atrial fibrillation than non-athletes, and younger athletes have a higher risk than older athletes. (Source: WebMD Health)
Source: WebMD Health - July 13, 2021 Category: Consumer Health News Source Type: news

Athletes Have Higher Risk for Developing Atrial Fibrillation
TUESDAY, July 13, 2021 -- Athletes have a significantly greater likelihood of developing atrial fibrillation versus nonathletes, according to a systematic review and meta-analysis published online July 12 in the British Journal of Sports... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2021 Category: Pharmaceuticals Source Type: news

Athletes Face Twice the Odds for A-Fib
TUESDAY, July 13, 2021 -- Athletes have a much higher risk of the heart rhythm disorder atrial fibrillation than non-athletes, and younger athletes have a higher risk than older athletes, according to a new report from Britain. Atrial fibrillation... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 13, 2021 Category: General Medicine Source Type: news

NIH funds research into new method to predict atrial fibrillation recurrence
(Cleveland Clinic) A team led by researchers from Cleveland Clinic and Case Western Reserve University have received a $2.95 million grant over four years from the National Institutes of Health to explore how imaging can be used to predict the risk of atrial fibrillation recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 12, 2021 Category: International Medicine & Public Health Source Type: news

Preablation Weight Loss Linked to Freedom From A-Fib
FRIDAY, July 9, 2021 -- Preablation weight loss is associated with freedom from atrial fibrillation (FFAF) in both obese and nonobese patients, according to a study published online June 30 in the Journal of Cardiovascular Electrophysiology. Graham... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2021 Category: Pharmaceuticals Source Type: news

Imaging test may predict patients most at risk of some heart complications from COVID-19
(Johns Hopkins Medicine) Researchers at Johns Hopkins Medicine have shown that a type of echocardiogram, a common test to evaluate whether a person's heart is pumping properly, may be useful in predicting which patients with COVID-19 are most at risk of developing atrial fibrillation -- an irregular heartbeat that can increase a person's risk for heart failure and stroke, among other heart issues. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 8, 2021 Category: International Medicine & Public Health Source Type: news

Catheter Ablation Improves A-Fib Outcomes in Racial/Ethnic Minorities
WEDNESDAY, July 7, 2021 -- Catheter ablation significantly improved major clinical outcomes compared with drug therapy among racial or ethnic minorities with atrial fibrillation (AF) enrolled in the CABANA trial, according to a study published in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 7, 2021 Category: Pharmaceuticals Source Type: news

ESC Congress 2021 - Press Programme announced
(European Society of Cardiology) The Press Programme for ESC Congress - the world's largest cardiovascular event - is revealed today. Journalists from around the globe are invited to the Opening Press Conference on Wednesday 25 August and four embargoed Hot Line Press Conferences during ESC Congress 2021. Featuring new data on heart failure, valvular heart disease, cardiac arrest, hypertension, and atrial fibrillation - with opportunities to question investigators about their research. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 6, 2021 Category: International Medicine & Public Health Source Type: news

Traumatic injury and atrial fibrillation among deployed service members - Alcover KC, Ambardar SR, Poltavskiy E, Nasir JM, Janak JC, Howard JT, Walker LE, Haigney MC, Stewart IJ.
In this study, we investigated the impact of traumatic injury on AF/AFL among service members with deployment ... (Source: SafetyLit)
Source: SafetyLit - July 5, 2021 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer
MARLBOROUGH, Mass., June 29, 2021 -- (Healthcare Sales & Marketing Network) -- CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its ... Devices, Cardiology, Personnel CardioFocus, HeartLight X3, ablation, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2021 Category: Pharmaceuticals Source Type: news

Novel Anticoagulants Achieve Rapid Market Penetration despite Higher Costs
(PDF) ... People with atrial fibrillation are five times more likely to suffer a stroke than the wider population and are ... (Source: AARP.org News)
Source: AARP.org News - June 24, 2021 Category: American Health Source Type: news

Boston Scientific Exercises Option to Acquire Farapulse, Inc.
Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology MARLBOROUGH, Mass., June 24, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporati... Devices, Cardiology, Mergers & Acquisitions Boston Scientific, Farapulse, pulsed field ablation, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 24, 2021 Category: Pharmaceuticals Source Type: news

Atrial Fibrillation Burden: An Update Atrial Fibrillation Burden: An Update
Is the traditional binary stroke risk paradigm of atrial fibrillation absent or present, irrespective of burden, an oversimplification?Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Targeted AF detection in COVID-19 vaccination clinics, GIRFT
This document brings together learning from several pilot sites which have been carrying out targeted detection of atrial fibrillation (AF) in COVID-19 vaccination clinics. The aim is to provide guidance for systems wishing to develop a standard operating procedure for offering targeted rhythm checks for AF detection in mass vaccination clinics. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 21, 2021 Category: Consumer Health News Source Type: news

No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure No Benefit to Postop Heparin Bridging in Patients Who Stop Warfarin for a Procedure
There does not appear to be a benefit to postoperative heparin bridging in patients with atrial fibrillation or a mechanical heart valve who temporarily stop taking warfarin before a planned procedure, according to results of the PERIOP2 study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - June 18, 2021 Category: Surgery Tags: Cardiology News Source Type: news

ACC, HRS, Bristol Myers Squibb-Pfizer Alliance to transform AFib care
(American College of Cardiology) The American College of Cardiology and Heart Rhythm Society, in collaboration with the Bristol Myers Squibb-Pfizer Alliance, are launching an innovative project to improve management of atrial fibrillation in underserved communities. TRANSFORM: Atrial Fibrillation Quality Initiative (TRANSFORM: AF) will give clinicians and health systems tools to improve adoption of guideline-directed medical therapy in targeted patient populations by putting the right resources in front of the right people at the right time to drive measurable changes in performance. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news

Accelerometer-Derived Physical Activity Tied to Drop in Risk for A-Fib
WEDNESDAY, June 16, 2021 -- Accelerometer-derived physical activity is associated with reduced risks for atrial fibrillation (AF) and stroke, according to a study published online May 25 in the European Heart Journal. Shaan Khurshid, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 16, 2021 Category: Pharmaceuticals Source Type: news

ACC 2021 Highlights: Drugs and Alcohol ACC 2021 Highlights: Drugs and Alcohol
Aspirin dosing, alcohol and atrial fibrillation, dual vs mono antiplatelet therapy post PCI, and sacubitril/valsartan post MI are among the drug highlights from ACC 2021.theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news

Mayo Clinic Q & amp;A podcast: Atrial fibrillation treatment improves quality of life for patients
Many people may be living with a serious heart condition and not know it. Because the signs and symptoms of atrial fibrillation can be vague, people often think they are simply out of shape or just getting older. Atrial fibrillation, sometimes referred to as "a-fib", is an irregular and often rapid heartbeat that can increase [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 14, 2021 Category: Databases & Libraries Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cardiac Monitor Implant Detects A-Fib in More Stroke Patients
WEDNESDAY, June 9, 2021 -- Among patients with ischemic stroke attributed to large- or small-vessel disease, an insertable cardiac monitor (ICM) more frequently detects atrial fibrillation (AF) over 12 months than usual care with external cardiac... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 9, 2021 Category: Pharmaceuticals Source Type: news

Abbott Receives European and Canadian Approval for Amplatzer ™ Steerable Delivery Sheath to Optimize Left Atrial Appendage Closure Procedures for People at Risk of Stroke
- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation (Source: Abbott.com)
Source: Abbott.com - June 7, 2021 Category: Pharmaceuticals Source Type: news

Evidence Mounts for Implantable AF Monitoring After Stroke Evidence Mounts for Implantable AF Monitoring After Stroke
Two new studies have shown higher atrial fibrillation (AF) detection rates when implantable devices are used; the studies have also expanded the population that may be targeted for such monitoring.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 2, 2021 Category: Primary Care Tags: Neurology & Neurosurgery News Source Type: news

CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
China Grand Pharma will seek regulatory approvals and commercialize CardioFocus' innovative catheter ablation technology for pulmonary vein isolation Pulmonary vein isolation is the gold standard treatment for atrial fibrillation MARLBOROUGH, Mass., ... Devices, Interventional, Cardiology, Licensing CardioFocus, China Grand Pharmaceutical, atrial fibrillation, HeartLight X3 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 2, 2021 Category: Pharmaceuticals Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Improved detection of atrial fibrillation could prevent disabling strokes
(University of Alberta Faculty of Medicine& Dentistry) A clinical trial examining the efficacy of two devices to monitor and detect atrial fibrillation (AF), or an irregular heartbeat, in ischemic stroke patients -- one an implantable device that monitors over 12 months, the other an external device that monitors over a 30-day period -- found the implantable device is more than three times more effective in detecting AF, and both are a significant improvement over the current standard of care in Alberta, Canada. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 1, 2021 Category: International Medicine & Public Health Source Type: news

Stroke: One 'simple' way to lower your risk first thing in the morning
A STROKE is five times more likely if you suffer from atrial fibrillation - an abnormal heart rhythm that feels as though the heart is fluttering. This occurs when the top chambers of the muscle quiver or twitch due to an electrical impulse. (Source: Daily Express - Health)
Source: Daily Express - Health - May 27, 2021 Category: Consumer Health News Source Type: news

Wearable devices show that physical activity may lower atrial fibrillation and stroke risk
(Massachusetts General Hospital) Guideline-adherent exercise is shown in a large study to be associated with substantially lower risks of atrial fibrillation and stroke. A new generation of " smart " devices with diagnostic capabilities could open the door to low-cost, highly effective disease prevention programs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 25, 2021 Category: International Medicine & Public Health Source Type: news

A Broken Heart After Child Loss A Broken Heart After Child Loss
A new study demonstrates a link between stress and incident atrial fibrillation in parents who had faced the loss of a child; among the most extreme sources of stress that a family can face.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Acute Alcohol Consumption Raises Risk for Atrial Fibrillation Acute Alcohol Consumption Raises Risk for Atrial Fibrillation
Dr Gregory Marcus discusses his study results showing that the risk for AF is increased in the few hours after even moderate alcohol intake.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 20, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

IMBRUVICA ® (ibrutinib)-Based Combination Regimen as a Fixed-Duration, First-Line Treatment for Chronic Lymphocytic Leukemia Demonstrates High Rates of Disease Control
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICA® plus venetoclax were alive and progression-free at two years.[1] Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).1 In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. Thes...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Silent atrial fibrillation as a risk factor for falls in the elderly - Turusheva AV, Frolova EV, Petrosyan YM, Dumbadze RD.
Falls increase the risk of injury, disability, and death in the elderly. Atrial fibrillation (AF) is one of the risk factors for falls in old age, however, the relationship between "silent" AF and falls has not been investigated. The study included patient... (Source: SafetyLit)
Source: SafetyLit - May 19, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Fish Oil Supplements Tied to Risk for Atrial Fibrillation
WEDNESDAY, May 19, 2021 -- Fish oil supplements are associated with a significantly greater risk for atrial fibrillation (AF) in patients at elevated cardiovascular risk, according to a research letter published online April 28 in the European Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 19, 2021 Category: Pharmaceuticals Source Type: news

Surgical Snip Might Prevent Stroke in People With A-fib
A simple surgery may help lower the risk for strokes by more than a third in patients with atrial fibrillation, (Source: WebMD Health)
Source: WebMD Health - May 17, 2021 Category: Consumer Health News Source Type: news

Finerenone-potential-reduce-onset-atrial-fibrillation-flutter-patients-chronic-kidney-disease-2
A prespecified exploratory analysis of the FIDELIO-DKD study demonstrates that finerenone may significantly reduce the risk of new onset atrial fibrillation or flutter (AFF) in patients with CKD and T2D versus placebo when added to standard of care / This analysis also concluded that finerenone reduced the risk of kidney or cardiovascular events with no significant difference in the effect of finerenone between patients with and without history of AFF at baseline / Based on the comprehensive finerenone clinical trial program, finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor (MR) a...
Source: Bayer Company News - May 17, 2021 Category: Pharmaceuticals Source Type: news

Surgical Snip Might Prevent Stroke in People With A-fib
MONDAY, May 17, 2021 -- A simple surgery may help lower the risk for strokes by more than a third in patients with atrial fibrillation, a common irregular heartbeat, a new trial finds. The reduction in stroke risk is achieved by blocking the left... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 17, 2021 Category: General Medicine Source Type: news

ACC: Occlusion of Left Atrial Appendage Prevents Stroke in A-Fib
MONDAY, May 17, 2021 -- For patients with atrial fibrillation undergoing cardiac surgery for other reasons, occlusion of the left atrial appendage during surgery is associated with a reduction in stroke or systemic embolism, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 17, 2021 Category: Pharmaceuticals Source Type: news

Alcohol may have immediate effect on atrial fibrillation risk, events
(American College of Cardiology) Alcohol appears to have an immediate--or near-immediate--effect on heart rhythm, significantly increasing the chance that an episode of atrial fibrillation (AFib) will occur, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 17, 2021 Category: International Medicine & Public Health Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Watchman Registry: 1-Year Stroke Estimates Reassuringly Low Watchman Registry: 1-Year Stroke Estimates Reassuringly Low
The findings were parsed from more than 36,000 patients with atrial fibrillation in the NCDR LAAO Registry implanted early in the rollout of the device.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

LAAOS III: Surgical LAA Closure Cuts AF Stroke Risk by One Third LAAOS III: Surgical LAA Closure Cuts AF Stroke Risk by One Third
The finding'opens a new paradigm'for stroke prevention in atrial fibrillation and should change clinical guidelines, experts say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 15, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Anticoagulation in Advanced Dementia Needs'Rational Strategy'Anticoagulation in Advanced Dementia Needs'Rational Strategy '
A new study has highlighted the need for more information on the net clinical benefit of anticoagulation treatment in patients with atrial fibrillation and advanced dementia at the end of life.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 13, 2021 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

Undiagnosed A-Fib Detected During Diabetic Foot Exam
WEDNESDAY, May 12, 2021 -- Atrial fibrillation (AF) can be detected during annual foot assessments in patients with diabetes, according to a study presented at EHRA 2021, an online scientific congress hosted by the European Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 12, 2021 Category: Pharmaceuticals Source Type: news

Atrio-esophageal Fistula and Atrial Fibrillation Ablation Atrio-esophageal Fistula and Atrial Fibrillation Ablation
A new study provides important insights into the incidence, presentation, diagnosis, and outcome of atrio-esophageal fistula following percutaneous catheter ablation.Europace (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 12, 2021 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Outcomes of new-onset atrial fibrillation in patients with sepsis: A systematic review and meta-analysis of 225,841 patients, The American journal of emergency medicine
Background: The outcomes of new-onset atrial fibrillation (AF) during sepsis are inconsistent and inconclusive. This meta-analysis aims to provide a comprehensive description of the impact of new-onset AF on the prognosis of sepsis.; Methods: Three electronic databases (PubMed, Embase, and the Cochrane Library) were searched for relevant studies. Meta-analysis was performed using odds ratios (OR) and 95% confidence intervals (CI) as effect measures.; Results: A total of 225,841 patients from 13 individual studies were incorporated to the meta-analysis. The summary results revealed that new-onset AF during sepsis was associ...
Source: Current Awareness Service for Health (CASH) - May 6, 2021 Category: Consumer Health News Source Type: news

Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial
- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure (Source: Abbott.com)
Source: Abbott.com - May 6, 2021 Category: Pharmaceuticals Source Type: news